Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results…
By M. Rothenberg, A. Oza, R. Bigelow, J. Berlin, J. Marshall, R. Ramanathan, L. Hart, S. Gupta, C. Garay, Brent Burger and 2 more. Journal of Clinical Oncology, 2003
664 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/f9604bc748ee3da8327a0cba978b4e0bde7a4829
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Surgery
Citations in the corpus
- Molecular mechanisms of cisplatin resistance (2012, background): “Oxaliplatin is currently employed against colorectal cancer in association with 5-fluorouracil and folinic acid (the so-called FOLFOX protocol) (Giacchetti et al., 2000; de Gramont et al., 2000; Rothenberg et al., 2003; Goldberg et al., 2004), and may also be useful for the treatment of lung cancer ”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, background): “The TRI‑ COLORE trial, a phase III trial conducted in Japan, compared the efficacy and safety of S‑1 + IRI + BEV with FOLFOX + BEV or CAPOX + BEV as first‑line therapy for PS 0–1 patients with unresectable colorectal cancer.”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, neutral): “• FOLFOX [62, 90] + Bmab [85, 91] • CapeOX (note 2) [92] + Bmab [85] ▪ SOX + Bmab ▪ FOLFOX + Cmab/Bmab”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (2011, neutral): “(1) FOLFOX [34, 48] ± bevacizumab [49], CapeOX(2) [50] ± bevacizumab, (2) CPT-11 ? cetuximab [51].”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer (2015, background): “Note 1 FOLFOX—infusional 5-FU + l-LV + OX Note 2 CapeOX—Cape + OX Note 3 FOLFIRI—infusional 5-FU + l-LV + RI Note 4 FOLFOXIRI—Infusional 5-FU + l-LV + IRI + OX Note 5 IRIS—S-1 + IRI Chapter 6: Radiotherapy • Radiotherapy is used to treat patients with locally advanced rectal cancer, either as adjuva”
- Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. (2007, background): “For example, initial treatment with fluorouracil and irinotecan results in a median survival approaching 15 months,(3,4) and secondline therapy with oxaliplatin further improves disease control.(5,6) Yet, despite these advances, nearly all patients with metastatic colorectal cancer will succumb to t”